A5060431846- Immune Cell Function and Interaction
- Cancer Immunotherapy and Biomarkers
- T-cell and B-cell Immunology
- Immunotherapy and Immune Responses
- IL-33, ST2, and ILC Pathways
- CAR-T cell therapy research
- Lymphoma Diagnosis and Treatment
- Inflammasome and immune disorders
Immunité et Cancer
2023-2024
Institut Curie
2023-2024
Inserm
2021-2024
Roche (France)
2021-2022
Nantes Université
2021-2022
Recently, the inhibitory CD94/NKG2A receptor has joined group of immune checkpoints (ICs) and its expression been documented in NK cells CD8+ T lymphocytes several cancers some infectious diseases. In colorectal cancer (CRC), we previously reported that NKG2A+ tumor-infiltrating (TILs) are predominantly αβ CD94 overexpression and/or ligand HLA-E were associated with a poor prognosis. This study aimed to thoroughly characterize TIL subpopulation document impact NKG2A on anti-tumor responses...
Mucosal-associated invariant T (MAIT) cells harbor evolutionarily conserved TCRs, suggesting important functions. As human and mouse MAIT functional programs appear distinct, the features remain unidentified. Using species-specific tetramers coupled to single-cell RNA sequencing, we characterized cell development in six species spanning 110 million years of evolution. Cross-species analyses revealed transcriptional events underlying maturation, marked by ZBTB16 induction all species. human,...
How T-cell receptor (TCR) characteristics determine subset commitment during development is still unclear. Here, we addressed this question for innate-like T cells, mucosal-associated invariant (MAIT) and natural killer (iNKT) cells. MAIT iNKT cells have similar developmental paths, leading in mice to two effector subsets, cytotoxic (MAIT1/iNKT1) IL17-secreting (MAIT17/iNKT17). For iNKT1 vs iNKT17 fate choice, an instructive role TCR affinity was proposed but recent data argue against model....
In colorectal cancer (CRC), a high density of T lymphocytes represents strong prognostic marker in subtypes CRC. Optimized immunotherapy strategies to boost this T-cell response are still needed. A good candidate is the inflammasome pathway, an emerging player immunology that bridges innate and adaptive immunity. Its effector protein caspase-1 matures IL-18 can promote T-helper/cytotoxic (Th1/Tc1) response. It unknown whether tumor cells from CRC possess functional caspase-1/IL-18 axis could...